Long term outcomes in malignant hemangiopericytoma

Yadav, Sanjay Kumar; Haider, Karin; Yadav, Ankita; Sami, Abdus; Mirchandani, D.; Ahmad, Irfan; Alvi, Rehman; Ahmed, Safia K.

doi:10.1200/jco.2005.23.16_suppl.9072

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the tumor's location was infratentorial, and Guthrie et al [1] have reported that regardless of the extent of the surgery, supratentorial tumors are associated with longer survival rates than tumors located on the posterior fossa or tentorium. The median survival rates after the recurrence of HPC in recent series have been found to be between 3.5 and 4.6 years [5,18]. However, the presence of extraneural metastases significantly reduces survival prospects [5].…”

Section: Discussionmentioning

confidence: 99%

Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma

Martínez‐Trufero

Alfaro²,

Felipo³

et al. 2010

Anti-Cancer Drugs

View full text Add to dashboard Cite

Meningeal hemangiopericytoma is an uncommon and aggressive malignancy that, in contrast to meningiomas, shows a high propensity for local recurrence and the development of late extraneural metastases. The results of chemotherapy in advanced hemangiopericytoma have been disappointing, and they have been particularly poor in cases located in the meninges. We report a case of a heavily pretreated metastatic meningeal hemangiopericytoma in which fourth-line chemotherapy with trabectedin, a marine-derived antineoplastic agent effective in treating advanced soft tissue sarcomas, resulted in clinical benefit.

show abstract